Abstract
Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme required for the de novo synthesis of guanine nucleotides from IMP. VX-944 (Vertex Pharmaceuticals, Cambridge, MA, USA) is a small-molecule, selective, noncompetitive inhibitor directed against human IMPDH. In this report, we show that VX-944 inhibits in vitro growth of human multiple myeloma (MM) cell lines via induction of apoptosis. Interleukin-6, insulin-like growth factor-1, or co-culture with bone marrow stromal cells (BMSCs) do not protect against VX-944-induced MM cell growth inhibition. VX-944 induced apoptosis in MM cell lines with only modest activation of caspases 3, 8, and 9. Furthermore, the pan-caspase inhibitor z-VAD-fmk did not inhibit VX-944-induced apoptosis and cell death. During VX-944-induced apoptosis, expressions of Bax and Bak were enhanced, and both apoptosis-inducing factor (AIF) and endonuclease G (Endo G) were released from the mitochondria to cytosol, suggesting that VX-944 triggers apoptosis in MM cells primarily via a caspase-independent, Bax/AIF/Endo G pathway. Importantly, VX-944 augments the cytotoxicity of doxorubicin and melphalan even in the presence of BMSCs. Taken together, our data demonstrate a primarily non-caspase-dependent apoptotic pathway triggered by VX-944, thereby providing a rationale to enhance MM cell cytotoxicity by combining this agent with conventional agents which trigger caspase activation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abraham MC and Shaham S . (2004). Trends Cell Biol., 14, 184–193.
Ahluwalia GS, Jayaram HN, Plowman JP, Cooney DA and Johns DG . (1984). Biochem. Pharmacol., 33, 1195–1203.
Ahn HJ, Kim YS, Kim JU, Han SM, Shin JW and Yang HO . (2004). J. Cell. Biochem., 91, 1043–1052.
Arnoult D, Gaume B, Karbowski M, Sharpe JC, Cecconi F and Youle RJ . (2003). EMBO J., 22, 4385–4399.
Cande C, Vahsen N, Garrido and Kroemer G . (2004). Cell Death Differ., 11, 591–595.
Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW and Anderson KC . (1997). Blood, 89, 227–234.
Cregan SP, Dawson VL and Slack RS . (2004). Oncogene, 23, 2785–2796.
Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, Larochette N, Prevost MC, Leber B, Andrews D, Penninger J and Kroemer G . (2000). FASEB J., 14, 729–739.
Eugui EM and Almquist SJ . (1990). Proc. Natl. Acad. Sci. USA, 87, 1305–1309.
Eugui EM, Almquist SJ, Muller CD and Allison AC . (1991). Scand. J. Immunol., 33, 161–173.
Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW and Thornberry NA . (1998). J. Biol. Chem., 273, 32608–32613.
Ge NL and Rudikoff S . (2000). Blood, 96, 2856–2861.
Gu JJ, Gathy K, Santiago L, Chen E, Huang M, Graves LM and Mitchell BS . (2003). Blood, 101, 4958–4965.
Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman and Anderson KC . (2002). Mol. Cancer Ther., 1, 851–860.
Hideshima T, Chauhan D, Schlossman R, Richardson and Anderson KC . (2001). Oncogene, 20, 4519–4527.
Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI and Anderson KC . (2000). Blood, 96, 2943–2950.
Hunakova L, Bies J, Sedlak J, Duraj J, Jakubikova J, Takacsova X, Novotny L and Chorvath B . (2000). Neoplasma, 47, 274–279.
Jaattela M and Tschopp J . (2003). Nat. Immunol., 4, 416–423.
Jain J, Almquist SJ, Shlyakhter and Harding MW . (2001). J. Pharm Sci., 90, 625–637.
Jelinek DF, Witzig TE and Arendt BK . (1997). J. Immunol., 159, 487–496.
Kagawa S, Gu J, Honda T, McDonnell TJ, Swisher SG, Roth JA and Fang B . (2001). Clin. Cancer Res., 7, 1474–1480.
Klein B, Zhang XG, Lu ZY and Bataille R . (1995). Blood, 85, 863–872.
Knudtzon S and Nissen NI . (1972). Cancer Chemother. Rep., 56, 221–227.
Laliberte J, Yee A, Xiong Y and Mitchell BS . (1998). Blood, 91, 2896–2904.
Liu X, Li P, Widlak P, Zou H, Luo X, Garrard WT and Wang X . (1998). Proc. Natl. Acad. Sci. USA, 95, 8461–8466.
Lockshin RA and Zakeri Z . (2004). Oncogene, 23, 2766–2773.
McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, Lee KP and Boise LH . (2003). Mol. Cancer Ther., 2, 1155–1164.
McLean JE, Hamaguchi N, Belenky P, Mortimer SE, Stanton M and Hedstrom L . (2004). Biochem. J., 379, 243–251.
Messina E, Gazzaniga P, Micheli V, Guaglianone MR, Barbato S, Morrone S, Frati L, Agliano AM and Giacomello A . (2004). Int. J. Cancer, 108, 812–817.
Miyashita T, Nagao K, Krajewski S, Salvesen GS, Reed JC, Inoue T and Yamada M . (1998). Cell Death Differ., 5, 1034–1041.
Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S and Weber G . (1991). Cancer Res., 51, 3886–3890.
Pirnia F, Schneider E, Betticher DC and Borner MM . (2002). Cell Death Differ., 9, 905–914.
Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E, Mitsiades C, Hideshima T, Davies F, Doss D, Freeman A, Bosch J, Patin J, Knight R, Zeldis J, Dalton W and Anderson K . (2004). Mayo Clin. Proc., 79, 875–882.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC . (2003). N. Engl. J. Med., 348, 2609–2617.
Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J and Anderson KC . (2002). Blood, 100, 3063–3067.
Senda M and Natsumeda Y . (1994). Life Sci., 54, 1917–1926.
Sweeney MJ, Gerzon K, Harris PN, Holmes RE, Poore GA and Williams RH . (1972). Cancer Res., 32, 1795–1802.
Szekeres T, Sedlak J and Novotny L . (2002). Curr. Med. Chem., 9, 759–764.
Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, Meisenberg B and Tricot G . (2004). Clin. Cancer Res., 10, 8301–8308.
Turka LA, Dayton J, Sinclair G, Thompson CB and Mitchell BS . (1991). J. Clin. Invest, 87, 940–948.
Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D and Anderson KC . (1993). Blood, 82, 3712–3720.
Wright DG, Boosalis MS, Waraska K, Oshry LJ, Weintraub LR and Vosburgh E . (1996). Anticancer Res., 16, 3349–3351.
Yalowitz JA and Jayaram HN . (2002). Curr. Med. Chem, 9, 749–758.
Yalowitz JA, Pankiewicz K, Patterson SE and Jayaram HN . (2002). Cancer Lett., 181, 31–38.
Zimmermann AG, Gu JJ, Laliberte J and Mitchell BS . (1998). Prog. Nucleic Acid Res. Mol. Biol., 61, 181–209.
Acknowledgements
We acknowledge K Lin, R Hoover, Y Yao, M Harding, J Thomson, M Partridge and C Sorensen at Vertex for critical reading of the manuscript or advice during the course of these studies. This study is supported by National Institutes of Health Grants Specialized Programs of Research Excellence (SPORE) IP50 CA10070-01, PO-1 78378, and RO-1 CA 50947; the Doris Duke Distinguished Clinical Research Scientist Award (KCA); the Multiple Myeloma Research Foundation (TH); and the Cure for Myeloma Research Fund (KCA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishitsuka, K., Hideshima, T., Hamasaki, M. et al. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene 24, 5888–5896 (2005). https://doi.org/10.1038/sj.onc.1208739
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208739
Keywords
This article is cited by
-
Involvement of PARP-1/AIF Signaling Pathway in Protective Effects of Gualou Guizhi Decoction Against Ischemia–Reperfusion Injury-Induced Apoptosis
Neurochemical Research (2020)
-
FF-10501 induces caspase-8-mediated apoptotic and endoplasmic reticulum stress-mediated necrotic cell death in hematological malignant cells
International Journal of Hematology (2019)
-
IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways
Journal of Experimental & Clinical Cancer Research (2018)
-
Apoptosis-inducing factor (AIF) and leukocyte elastase inhibitor/l-DNase II (LEI/LDNaseII), can interact to conduct caspase-independent cell death
Apoptosis (2013)
-
Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients
Journal of Cancer Research and Clinical Oncology (2013)